Health
Ultragenyx's Angelman Syndrome Drug Fails in Critical Trial
By Editor • September 2, 2026 • 1 min read
Ultragenyx's GTX-102 for Angelman syndrome has failed a Phase 3 trial, dashing hopes for affected families and the company's profitability.
Read more